Our experimental data therefore provide mechanistic insights into the clinical association between high CBX4 expression in GC tissues and adverse clinicopathological features, confirming CBX4 as a key pro-oncogenic factor in GC progression. The gene discussed is CBX4; the disease is gastric cancer.